<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01780675</url>
  </required_header>
  <id_info>
    <org_study_id>M12PHA</org_study_id>
    <nct_id>NCT01780675</nct_id>
  </id_info>
  <brief_title>Hippocampus Avoidance PCI vs PCI</brief_title>
  <acronym>HA-PCI</acronym>
  <official_title>Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard
      dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low.
      However, a clear relationship between radiation dose and damage to the hippocampal stem cells
      has not been established yet.

      This study is initiated to investigate the early and delayed neurotoxicity of PCI and to
      assess in a randomised design the benefits and risks of sparing the hippocampus in Small Cell
      Lung Cancer patients who receive PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neurocognitive decline</measure>
    <time_frame>4 months</time_frame>
    <description>Each patient's total recall score recorded at 4 months will be compared to baseline and dichotomized into success (decline less or equal 5 points) or failure (decline more than 5 points). The difference between the groups, in terms of dichotomized decline will be tested by means of the Fisher's exact test. A p-value less than 0.049 will be considered significant. The primary analysis will be based on an intention-to-treat principle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
    <description>Brain metastases Time from randomization to the occurrence of brain metastases will be calculated and depicted in a cumulative incidence plot. Sensitivity analysis will be performed to assess the value of PCI vs HA-PCI treatment once considering patients dying without distant brain metastases to be censored and once using competing risk analysis considering distant metastases and death as separate events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hippocampal Avoidance PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Prophylactic Cranial Irradiation</intervention_name>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Hippocampal Avoidance PCI</intervention_name>
    <arm_group_label>Hippocampal Avoidance PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  − Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or
             radiological evidence of brain metastases) candidate for PCI, i.e. without progressive
             disease after chemo-radiotherapy in stage I-III or after a remission after
             chemotherapy in stage IV

               -  Sufficient proficiency in Dutch

        Exclusion Criteria:

          -  Prior radiotherapy to the brain

          -  Clinical evidence for brain metastases or primary brain tumors− Evidence of
             progressive extracranial metastatic disease

          -  Previous malignancy &lt; 2 years ago except for adequately treated basal cell carcinoma
             of the skin and carcinoma in situ of the cervix

          -  Any systemic anticancer treatment during PCI or within 3 weeks before start PCI

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <phone>+31 20 512 2174</phone>
    <email>j.belderbos@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanne Schagen, PhD</last_name>
    <phone>+ 31 20 512 2328</phone>
    <email>s.schagen@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan van Meerbeeck, MD, PhD</last_name>
      <phone>+ 32 3 821 56 81</phone>
      <email>jan.vanmeerbeeck@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolande Lievens, MD, PhD</last_name>
      <phone>+32 9 332 21 11</phone>
      <email>y.lievens@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Peeters, MD, PhD</last_name>
      <phone>+32 1 634 69 02</phone>
      <email>stepanie.peeters@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Deprez, MD, PhD</last_name>
      <phone>+32 1 634 90 70</phone>
      <email>sabine.deprez@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <phone>+31 20 512 2135</phone>
      <email>j.belderbos@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sanne Schagen, PhD</last_name>
      <phone>+31 20 512 2328</phone>
      <email>s.schagen@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Dieleman, MD, PhD</last_name>
      <phone>+31 20 566 7990</phone>
      <email>e.m.dieleman@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien de Jaeger, MD, PhD</last_name>
      <phone>+31 40 239 6400</phone>
      <email>katrien.d.jaeger@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Katrien de Jaeger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Praag, MD</last_name>
      <phone>+31 10 704 1507</phone>
      <email>j.praag@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marjan vd Pol, MD, PhD</last_name>
      <phone>+ 31 10 704 1507</phone>
      <email>m.vandepol@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituut Verbeeten</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friderieke Koppe, MD</last_name>
      <phone>+31 13 594 7559</phone>
      <email>kopp.f@bvi.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>Hippocampal Avoidance Prophylactic Cranial Irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

